Brief Report: Clinical Response, Toxicity, and Resistance Mechanisms to Osimertinib Plus MET Inhibitors in Patients With EGFR-Mutant MET-Amplified NSCLC. - Wang K; Du R; Roy-Chowdhuri S; Li ZT; Hong L; Vokes N; Elamin YY; Hume CB; Skoulidis F; Gay CM; Blumenschein G; Fossella FV; et al. (JTO clinical and research reports, 2023)